Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278837 · ClinicalTrials.gov registry record · NA
Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors
A NA study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 94
- Enrollment target
NCT00278837: Completed NA study, sponsored by Weill Medical College of Cornell University.
NCT00278837 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 94 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00278837, a NA study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
Study Summary
Women with breast cancer often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with breast cancer decrease their suffering and improve their quality of life.
Interventions
- BEHAVIORAL Mindfulness based meditation program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2003-05 |
| Est. Completion | 2010-03 |
| Phase | NA |
What the finished NCT00278837 record still lists
NCT00278837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Mindfulness based meditation program is the first listed.
NCT00278837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00278837 about?
NCT00278837 is a clinical study titled "Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors". Women with breast cancer often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with breast cancer decrease their suffering and improve their quality of life.
What is the current status of trial NCT00278837?
This trial is currently completed. It is a NA study. The enrollment target is 94 participants. The study started on 2003-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00278837?
The interventions under investigation include: Mindfulness based meditation program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00278837?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00278837's enrollment target sits among peer trials
94 935th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia